PLAINSBORO, N.J., Jan. 26, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest insulin, Tresiba® (insulin degludec injection), a ...
Tresiba (insulin degludec) is a prescription drug that’s used to manage high blood sugar in people with diabetes. Tresiba’s cost may depend on your dosage, your health insurance, and the pharmacy you ...
If you have diabetes, your doctor may prescribe Tresiba. Tresiba is a prescription drug that’s used to manage blood sugar levels. Tresiba is used in adults and some children to treat type 1 or type 2 ...
Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage ...
Tresiba (insulin degludec) is a brand-name drug that’s prescribed for diabetes. The medication is available as a liquid vial and a prefilled injection pen. The cost of Tresiba with and without ...
As with other drugs, Tresiba (insulin degludec) can cause side effects, such as headache, upper respiratory infection, and injection site reaction. If side effects of Tresiba become difficult to ...
Novo Nordisk announced the launch of Tresiba (insulin degludec) injection indicated to improve glycemic control in adults with diabetes. Novo Nordisk announced the launch of Tresiba (insulin degludec) ...
Bagsværd, 29 November 2016 - Today, Novo Nordisk announced the headline results from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the ...
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an expanded use for Tresiba (insulin degludec) injection to improve glycemic control in children and adolescents with ...
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, ...
New data presented at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the U200 formulation of Tresiba(R) (insulin ...
Bagsværd, Denmark, 21 January 2013 – Novo Nordisk today announced that the European Commission has granted marketing authorisations for Tresiba® (insulin degludec) and Ryzodeg® (insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback